 






Thomas R. Staab, II, CFO and Treasurer, BioCryst Pharmaceuticals


























&timesJavascript is disabled
























Market Profiles



Login
Sign up



Login


Sign up








 







 Edit

Person













Thomas R. Staab, II



CFO and Treasurer
at
BioCryst Pharmaceuticals


Location: Raleigh-Durham, NC





Add to My Lists

Claim

Share


Copy the following code on your page/blog


Suggested widget size



Mobile



Desktop









Thomas R. Staab, II



CFO and Treasurer
at
BioCryst Pharmaceuticals


Location: Raleigh-Durham, NC




Add to My Lists

Claim

Share


Copy the following code on your page/blog


Suggested widget size



Mobile



Desktop




Tom Staab joined the BioCryst Leadership Team in July 2011, bringing his skill and experience regarding the financial stewardship of publically-traded companies, development and commercialization of pharmaceutical products and raising capital through strategic partnerships, equity and debt financings. Mr. Staab most recently served as Executive Vice President, CFO and Treasurer of Inspire Pharmaceuticals from May 2003 through its $430 million acquisition by Merck & Co., Inc. in May 2011. Prior to joining Inspire, he held the senior financial positions of Acting CFO and Treasurer at Triangle Pharmaceuticals, Inc. through its $480 million acquisition by Gilead Sciences, Inc. Additionally, Mr. Staab spent eight years working for PricewaterhouseCoopers LLP providing audit and business advisory services to national and multi-national corporations in the biotechnology, pharmaceutical, pulp and paper and communications industries. Tom currently serves on the Board of the NC Biosciences Organization (NCBIO) and is a member of its Audit Committee, and he has received several awards for his contribution and leadership to other organizations.
He is a Certified Public Accountant and received a B.S. in Business Administration and a Masters of Accounting from the University of North Carolina at Chapel Hill.



5

Companies in Career





N/A

Related Markets





4

Colleagues





N/A

Related Investments








Alias
N/A



Industry
Pharmaceuticals




Tags
Mergers Due Diligence Pharmaceutical Industry Forecasting Financial Modeling Venture Capital Biotechnology




Topics of Influence












N/A







N/A



























Careers








Achievements








Investments








Related People






 Edit
View all 



Thomas R. Staab, IICareer (5)






Jul-2011




BioCryst Pharmaceuticals



CFO and Treasurer







May-2003 to May-2011




Inspire



Executive Vice President, CFO & Treasurer







May-2003 to May-2011




Inspire Pharmaceuticals



CFO and Treasurer







Jan-1998 to May-2003




Triangle Pharmaceuticals, Inc./Gilead Sciences, Inc.,



Vice President and Treasurer/Acting Chief Financial Officer







May-1990 to Jan-1998




PricewaterhouseCoopers, LLP



Manager - TICE practice








Competencies










 Edit
View all 



Thomas R. Staab, IIEducation






1990



University of North Carolina at Chapel Hill


BSBA; MAC, Business









 Edit



Thomas R. Staab, IIAchievements and Recognitions





Add Milestone


No milestones has been recorded for Thomas R. Staab, II






 Edit



Thomas R. Staab, IILinks





Add Link


No links has been recorded for Thomas R. Staab, II









Thomas R. Staab, IIInvestments/Acquisitions





No investments has been recorded for Thomas R. Staab, II









Thomas R. Staab, IIInvestments Representing Others





No investment reps has been recorded for Thomas R. Staab, II








Thomas R. Staab, IIRelated People








Colleagues at BioCryst Pharmaceuticals







Lynne Powell

Chief Commercial Officer
Jan-2015









Robert Stoner

Vice President Human Resources
Jan-2008









Elliott Berger

Sr. Vice President Regulatory Affairs
2007









Alane Barnes

VP, General Counsel and Corporate Secretary
2006








View all 
Peers (21)







Manmeet Soni

CFO and Treasurer of Pharmacyclics









Stuart M. Huizinga

CFO of eHealth









Dave  Francis

Chief Financial Officer of eHealth









David L. White

CFO of Align Technology









Bob Goeltz

CFO of Onyx Pharmaceuticals









Stephen Gordon

Chief Financial Officer of TransMedics












View all 



Thomas R. Staab, IIRecommended Market Profiles








Life Sciences (Kleiner Perkins Caufield & Byers)

10,000 or More employees
58 companies





















STAAB THOMAS R II Top Holdings  

































WhaleWisdom









Search All
Search 13F Filers Only
Search SEC Filer
Search Stocks Only
Search Mgmt Inv. Cos Only
ETFs Only
Search Active




















                      STAAB THOMAS R II
                    

•   DURHAM, NC
                      
How do I update this listing?




                                             Staab Thomas R II is based out of Durham.   
                                           














Summary
13D/G
Insider (Form 4)



   Create Email Alert
 




×
Email Notification.







                   ***Log In or
                   Sign-up
                   to see more advanced email alert options such as selecting any type of
                   SEC form, multiple filers or classes of filers, and much more.***
                 

                    ...or to simply have an email sent to you whenever we receive a new
                           13F filing from STAAB THOMAS R II, enter your
                    email address below and choose 'Submit'.
                

Your email:








Cancel














Contact Info




staab thomas r ii


C/O INSPIRE PHARMACEUTICALS, INC.

DURHAM
NC
                                                        
                                                    27703


                                                      Business Phone:
                                                      2054444600
SEC SIC CODE:2836-BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)







Recent SEC Filings




4 filed on 05/24/2017
4 filed on 03/22/2017
4 filed on 03/20/2017
4 filed on 03/14/2017
4 filed on 03/10/2017
4 filed on 03/08/2017
4 filed on 03/01/2017
4 filed on 01/24/2017
4 filed on 01/03/2017
4 filed on 12/21/2016
















Schedule 13D and 13G events since 03/31/2017

Subscription required



 
Form 4 - Non-derivative Insider Transactions Since 03/31/2017
Loading...








Elevate your investments
Try it for free

















   Thomas Staab | North Carolina Biosciences Organization | ZoomInfo.com










 









Biocryst Pharmaceuticals Inc (BCRX) Senior Vice President and CFO STAAB THOMAS R II's Insider Stock Buys and Sells 



























Home




 Homepage


 Membership Levels


 Membership Data Coverage


 Complete Stock List


 Founder's Message


 The Book


 FREE Trial






Screeners


Value Screens 


 All-In-One Screener


 Industry Overview


 Ben Graham Net-Net


 Undervalued Predictable


 Buffett-Munger Screener


 Magic Formula (Greenblatt)


 Historical Low P/S List


 Historical Low P/B List


 Peter Lynch Screen


 High Short Interest


 52-Week/3Y/5Y Lows


 52-Week/3Y/5Y Highs


 Predictable Companies


 S&P 500 Grid


 Dividend Stocks


 Spin Off List




Downloads | Tools


  Excel Add-In GURUF


 Manual of Stocks™


 Download Financial Data


 Download Guru Portfolios


 Download Stock PDFs


 Download Insider Data


  API


 Mobile App




Strategies


 Performances


 Buffett-Munger


 Undervalued Predictable


 Low P/S


 Low P/B


 Broadest Owned


 Most Weighted






Gurus




 Latest Guru Picks


 Real Time Picks


 List of Gurus (Personalize)


 Gurus Portfolios


 Scoreboard


 Top 10 Holdings View


 Sector Picks


 International Picks


 Aggregated Portfolio


 Consensus Picks


 Guru Bargains


 Hot Picks


 Industry Trends


 Geographic Trend


 ETFs


 Options


 European Shorting






Insiders




 All Insiders


 CEO Buys/Sales


 CFO Buys/Sales


 Insider Cluster


 Guru+Insider Double Buys


 Triple Buys/Sales


 Insider Trends


 Canadian Insider


 Dutch Insider






Market


Market Valuation


 Economic Data


 Industry Overview


 Market-Cap/GDP Valuation


 Global Market Valuation


 Shiller P/E


 Shiller P/E By Sectors


 Buffett Assets Allocation




By Country


 USA


 Australia


 Canada


 China


 Germany


 India


 Japan


 UK


 More...






Articles


Articles


 Editor's Picks


 GuruFocus Research


 Value Ideas


 Interviews with Gurus


 Top Ranked


 Value Idea Contest


 Videos


 Following Authors




Submit Articles


 Writers Wanted


 Value Contest Winners


 Submit Articles Online


 My Articles






Conference




 Value Conference


 Speakers


 Location/Venue


 Register


 After Conference Gathering (Free Drinks)






Tutorials




 Tutorials & Webinars


 FAQ


 Contact Us






Log In




 Free Sign-up


 Log In


 7-Day Free Trial 






Subscribe




 Free Trial ($399/Year)


 Refer a Friend & Earn $50














Search
Compare

Search ▾










Get 7-Day Free Trial



My Portfolios▾

Portfolios Overview
Create New Portfolio
Portfolio Contest


My Gurus▾

Quick Browse
Personalize

My Gurus

Premium Gurus 
Premium Plus Investors 





















SummaryCanadian Dutch CEO Buys CFO Buys Insider Cluster Buys Double Buys Triple Buys Data Export Trend  




Saved!




USA

Canada

UK/Ireland

Europe

Asia

Oceania

Latin America

Africa



Currently Selected:



Show All Countries ▾





Purchase to select this region

Purchase $399
USA

OTCPK
NAS
NYSE
ARCA
OTCBB
AMEX
BATS




Purchase to select this region

Purchase $289
Canada

TSXV
TSX
XCNQ




Purchase to select this region

Purchase $269
UK/Ireland

UK




Purchase to select this region

Purchase $399
Europe

Germany
France
Poland
Russia
Sweden
Turkey
Bosnia and Herzegovina
Italy
Luxembourg
Switzerland


Belgium
Greece
Norway
Spain
Denmark
Bulgaria
Netherlands
Romania
Finland
Serbia
Austria
Croatia
Portugal
Slovakia
Cyprus
Macedonia
Slovenia
Ukraine
Hungary
Lithuania
Latvia
Malta
Iceland
Estonia
Czech Republic

All Countries ▾



Purchase to select this region

Purchase $399
Asia

India
Japan
Korea
Thailand
Hongkong
China
Taiwan
Malaysia
Singapore
Israel


Indonesia
Pakistan
Vietnam
Philippines
Sri Lanka
Kuwait
Nepal
Saudi
Jordan
Oman
Iran
Iraq
United Arab Emirates
Kazakhstan
Bahrain

All Countries ▾



Purchase to select this region

Purchase $269
Oceania

Australia
New zealand




Purchase to select this region

Purchase $299
Latin America

Brazil
Mexico
Argentina
Chile
Peru
Columbia
Jamaica
Venezuela
Ecuador




Purchase to select this region

Purchase $249
Africa

South Africa
Egypt
Nigeria
Mauritius
Morocco
Zimbabwe
Kenya
Tunisia
Ghana
Côte d'Ivoire




 Set As Default







Insider Trades


Try Insider Screener



Biocryst Pharmaceuticals Inc (BCRX) Senior Vice President and CFO STAAB THOMAS R II's Insider Stock Buys and SellsTo find out why GuruFocus thinks data on insider trades is interesting, read

Can Aggregated Insider Trading Activities Predict the Market?
Stocks That Both Gurus and Insiders Are Buying
Can Aggregated Insider Trading Activities Predict the Market of Different Sectors?




Filter by:



  Default





Search Insider Trade:




Go




Select to drill down:


All Market CapMicro Cap Small Cap Mid Cap Large Cap Mega Cap S&P 500 Companies All SectorsBasic Materials Consumer Cyclical Financial Services Real Estate Consumer Defensive Healthcare Utilities Communication Services Energy Industrials Technology   Display Those with At Least
100 500 1,000 2,000 5,000 10,000 20,000 50,000 100,000  Shares Display Stocks That are within Please Select 1% 
2% 
3% 
4% 
5% 
8% 
10% 
 of Please Select 52-Week Low3-Year Low5-Year LowReal time insider type:BuySellInsider Sentiment Chart 


 Recent Filings Activity
 

Total Records: 867710   Page:1  2   3   4   5   6   7   8   9   10   LAST (28924) 30 per page ▾ 10 20 2530 50 100



Symbol
Company
Insider
Position
Date
Buy/Sell
Shares
Trade Price ($)
Cost ($1000)
Price ChangeSince Trade (%)
Yield (%)
P/E
Market Cap ($M)
Details

BCRXBiocryst Pharma...STAAB THOMAS R IISenior Vice Pre...2017-03-20Sell3,250$9.229.9-41.2
0.000.00435.080 Link

BCRXBiocryst Pharma...STAAB THOMAS R IISenior Vice Pre...2017-03-10Sell3,250$9.0629.45-40.29
0.000.00435.080 Link

BCRXBiocryst Pharma...STAAB THOMAS R IISenior Vice Pre...2017-03-08Sell6,500$8.4354.8-35.82
0.000.00435.080 Link

BCRXBiocryst Pharma...STAAB THOMAS R IISenior Vice Pre...2017-03-06Sell3,250$7.925.68-31.52
0.000.00435.080 Link

BCRXBiocryst Pharma...STAAB THOMAS R IISenior Vice Pre...2016-12-19Sell3,250$7.4524.21-27.38
0.000.00435.080 Link

BCRXBiocryst Pharma...STAAB THOMAS R IISenior Vice Pre...2016-08-12Sell5,864$5.1830.384.44
0.000.00435.080 Link

BCRXBiocryst Pharma...STAAB THOMAS R IISenior Vice Pre...2016-08-09Sell14,577$4.4364.5822.12
0.000.00435.080 Link

BCRXBiocryst Pharma...STAAB THOMAS R IISenior Vice Pre...2015-12-21Sell3,052$10.8633.14-50.18
0.000.00435.080 Link

BCRXBiocryst Pharma...STAAB THOMAS R IISenior Vice Pre...2015-12-17Sell3,000$10.4931.47-48.43
0.000.00435.080 Link

BCRXBiocryst Pharma...STAAB THOMAS R IISenior Vice Pre...2015-07-20Sell3,500$16.557.75-67.21
0.000.00435.080 Link

BCRXBiocryst Pharma...STAAB THOMAS R IISenior Vice Pre...2015-06-22Sell3,750$1660-66.19
0.000.00435.080 Link

BCRXBiocryst Pharma...STAAB THOMAS R IISenior Vice Pre...2015-06-19Sell16,375$14.36235.15-62.33
0.000.00435.080 Link

BCRXBiocryst Pharma...STAAB THOMAS R IISenior Vice Pre...2015-06-05Sell6,000$12.7576.5-57.57
0.000.00435.080 Link

BCRXBiocryst Pharma...STAAB THOMAS R IISenior Vice Pre...2015-05-18Sell3,000$1133-50.82
0.000.00435.080 Link

BCRXBiocryst Pharma...STAAB THOMAS R IISenior Vice Pre...2014-12-29Sell9,500$12.56119.32-56.93
0.000.00435.080 Link

BCRXBiocryst Pharma...STAAB THOMAS R IISenior Vice Pre...2014-08-27Sell10,000$13.58135.8-60.16
0.000.00435.080 Link

BCRXBiocryst Pharma...STAAB THOMAS R IISenior Vice Pre...2014-07-01Sell3,125$1340.63-58.38
0.000.00435.080 Link

BCRXBiocryst Pharma...STAAB THOMAS R IISenior Vice Pre...2014-06-23Sell3,125$12.4939.03-56.69
0.000.00435.080 Link

BCRXBiocryst Pharma...STAAB THOMAS R IISenior Vice Pre...2014-06-17Sell3,125$1237.5-54.92
0.000.00435.080 Link

BCRXBiocryst Pharma...STAAB THOMAS R IISenior Vice Pre...2014-03-14Sell3,125$11.2435.13-51.87
0.000.00435.080 Link

BCRXBiocryst Pharma...STAAB THOMAS R IISenior Vice Pre...2014-03-04Sell3,000$12.6938.07-57.37
0.000.00435.080 Link
Total Records: 867710   Page:1  2   3   4   5   6   7   8   9   10   LAST (28924) 30 per page ▾ 10 20 2530 50 100Add this list into my watchlist/portfolio:

1. Add or remove tickers (Comma separated, up to 500 symbols)
BCRX





2. Select destination portfolioYou need to log in to proceed
3. Click the button to finish
 


Related News and Stories: B: comment on B 01-29-2017B: comment on B 12-11-2016B: Note of B 09-09-2016B: BCM Resources Corporation Provides Update on Thompson Knolls Option Agreement 06-14-2016B: BCM Resources Corporation Issues Shares for Debt 05-26-2016B: BCM Resources Corporation: Grant of Incentive Stock Options 05-16-2016B: BCM Resources Corporation Arranges Shares for Debt 04-24-2016B: BCM Resources Corporation Announces Results of Annual and Special Meeting 03-30-2016B: BCM Resources Corporation Appoints New Director and Grants Incentive Stock Options 03-02-2016B: comment on B 03-01-2016B: BCM Resources Corporation: Inland Explorations Successfully Completes Geophysical Surveys at Thompson Knolls 12-17-2015B: BCM Resources Corporation Appoints New Director and V.P. of Exploration 10-30-2015B: BCM Resources Corporation Finalizes Thompson Knolls Agreement & Announces Non-Brokered Private Placement 09-02-2015B: BCM Resources Corporation: Clarification of News Release Announcing Finalization of Thompson Knolls Agreement & Non-Brokered Private Placement 09-02-2015B: BCM Resources Corporation to Option Cu-Au Property in Utah 07-27-2015 Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company. 


 



Select portfolio(s):








                        Create a new portfolio



Why you are interested?



            Your selection and notes will be stored in your portfolio.
        


Login to add portfolio















Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
                    | Earn affiliate commissions by embedding GuruFocus Charts

                                                GuruFocus Affiliate Program: Earn up to $400 per referral.  ( Learn More) 













Home  About   Jobs    Advertise    Site Map    Term of Use    Privacy Policy     RSS    Mobile App     Email Alerts    Referral Program    Affiliate Program    FAQ    Contact Us
                               

                © 2004-2017                GuruFocus.com, LLC. All Rights Reserved.
            


                    Disclaimers: GuruFocus.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The gurus may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC.



                    Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.


















GF Chat {{numOfNotice}}




























×
Manage BookMarks





Close








FEEDBACK
















Thomas R. Staab II, CPA: Executive Profile & Biography - Bloomberg









































  





















































































July 22, 2017 9:12 PM ET
Biotechnology

Company Overview of BioCryst Pharmaceuticals, Inc.



SnapshotPeople 




OverviewBoard MembersCommittees



Executive Profile
Thomas R. Staab II, CPAChief Financial Officer, Principal Accounting Officer, Senior Vice President and Treasurer, BioCryst Pharmaceuticals, Inc.AgeTotal Calculated CompensationThis person is connected to 0 Board Members in 0 different organizations across 2 different industries.49$719,465As of Fiscal Year 2016
Background

		Mr. Thomas R. Staab, also known as Tom, II, CPA, has been the Chief Financial Officer, Senior Vice President and Treasurer of BioCryst Pharmaceuticals, Inc. since July 1, 2011 and also has been its Principal Accounting Officer since January 25, 2013. Mr. Staab has nearly twenty years of finance and biotech accomplishments to BioCryst. His experience includes equity financing, strategic alliances, mergers and acquisitions, drug commercialization, SEC reporting, treasury ... management and investor relations. He served as Chief Financial Officer and Treasurer of Inspire Pharmaceuticals, Inc. since May 2003, Executive Vice President since September 1, 2008 and served as its Principal Accounting Officer. He served as Vice President of Inspire Pharmaceuticals, Inc., since May 2003. He joined Inspire Pharmaceuticals Inc., in May 2003. Previously, Mr. Staab held senior financial positions with Triangle Pharmaceuticals Inc. He served for five years at Triangle as its Vice President and Treasurer from August 2000 to May 2003 and its Acting Chief Financial Officer from July 2002 to May 2003. Prior to Triangle, he served at Price Waterhouse LLP for eight years, w here he worked with publicly and privately held companies focusing on audits, business advisory and tax services. He serves on the Board of the North Carolina Biosciences Organization. He also serves on the Board of the Triangle Community Foundation. He is a Certified Public Accountant. Mr. Staab received his BS in Business Administration and Master of Accounting degrees from The University of North Carolina, Chapel Hill.Read Full Background




Corporate Headquarters
4505 Emperor BoulevardDurham, North Carolina 27703United StatesPhone: 919-859-1302Fax: 919-859-1314
Board Members Memberships
				There is no Board Members Memberships data available.
				Education
BS University Of North Carolina At Chapel HillMaster's Degree University Of North Carolina At Chapel Hill
Other Affiliations
Inspire Pharmaceuticals, Inc.Triangle Pharmaceuticals, Inc.University Of North Carolina At Chapel Hill


Annual Compensation
Salary$423,417Total Annual Compensation$423,417
Stocks Options
All Other Compensation$13,250Exercised Options$18,250Exercised Options Value$89,578Exercisable Options$226,503Exercisable Options Value$631,876Unexercisable Options$238,157Unexercisable Options Value$463,893Total Value of Options$1,236,386Total Number of Options$630,910
Total Compensation
Total Annual Cash Compensation$436,667Total Short Term Compensation$423,417Other Long Term Compensation$13,250Total Calculated Compensation$719,465




Request Profile Update
















 












The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking 
	here.




Stock Quotes


Market data is delayed at least 15 minutes.







Company Lookup



COMPETITOR COMPENSATIONNamePosition/CompanyCompensationSijmen   de Vries M.D., MBAChairman of Management Board and Chief Executive OfficerPharming Group N.V.$712.0KEmma  Walmsley Chief Executive Officer & DirectorGlaxoSmithKline plc--Flemming  Ornskov M.D., MBA, MPHCEO, MD & Executive DirectorShire plc$4.3MJoji  Nakayama Chairman & CEODaiichi Sankyo Company, Limited$126.0MCompensation as of Fiscal Year 2016.










Sponsored Financial Commentaries

Sponsored Links






Browse Companies
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
 | 
0
1
2
3
4
5
6
7
8
9






Request Profile Update

						Only a company representative may request an update for the company profile. Documentation will be required.
					  
To contact BioCryst Pharmaceuticals, Inc., please visit .  Company data is provided by S&P Global Market Intelligence.  Please use this form to report any data issues.
					  


Information Missing - Please enter your information in the following field(s): 




Company Name

Your Name*

Your E-Mail Address*

Your Phone Number*

Type of Data*


Overview
Executives
Key developments
Similar companies
Transactions


Update Needed*

All data changes require verification from public sources.  Please include the correct value or values and a source where we can verify.


Cancel


Submit






Your requested update has been submitted
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.


Close




























THOMAS R  STAAB II - CEO, founder, businessman - profile

















directorpedia.net - List of CEOs, founders, board members and company directors











THOMAS R  STAAB II
Check out list of companies and businesses related to THOMAS R  STAAB II. Find out THOMAS R  STAAB II address and contact details. View other people related to THOMAS R  STAAB II - coworkers, colleagues, companions, etc.
Address:   

C/O INSPIRE PHARMACEUTICALS, INC. 4222 EMPEROR BLVD. / SUITE 200 DURHAM 27703 NC




Companies related to THOMAS R  STAAB II
CIKCompany NamePositionCompany Address0000882796BIOCRYST PHARMACEUTICALS INCSenior Vice President and CFO 4505 EMPEROR BOULEVARD SUITE 200 DURHAM 277030001040416INSPIRE PHARMACEUTICALS INCChief Financial Officer 4222 EMPEROR BLVD STE 200  DURHAM 27703-8466




THOMAS R  STAAB II on the Web
Persons related to THOMAS R  STAAB II - BIOCRYST PHARMACEUTICALS INCNamePositionCity14159 capital (GP), LLC10% Owner NEW YORK14159, L.P.NEW YORK667, L.P.NEW YORKGEORGE B  ABERCROMBIEDirector DURHAMGEORGE B  ABERCROMBIEDirector CHAPEL HILLGEORGE B  ABERCROMBIEDirector CHAPEL HILLW JAMES  ALEXANDERSR. VP, Chief Medical Officer BIRMINGHAMYarlagadda S  BabuSenior VP - Drug Discovery BIRMINGHAMYarlagadda S  BabuSenior VP - Drug Discovery DURHAMBaker Biotech Capital (GP), LLC10% Owner NEW YORKBaker Bros. Advisors (GP) LLCNEW YORKBAKER BROS ADVISORS LLC10% Owner NEW YORKBAKER BROS. ADVISORS LPNEW YORKBaker Bros. Capital (GP), LLC10% Owner NEW YORKBaker Bros. Capital (GP), LLC10% Owner NEW YORKBaker Bros. Investments II, L.P.NEW YORKBaker Bros. Investments, L.P.NEW YORKBaker Brothers Life Sciences Capital (GP), LLC10% Owner NEW YORKBaker Brothers Life Sciences Capital (GP), LLC10% Owner NEW YORKBaker Brothers Life Sciences LPNEW YORKFELIX  BAKERFELIX  BAKER10% Owner NEW YORKFELIX  BAKERNEW YORKJULIAN  BAKERJULIAN  BAKERNEW YORKJULIAN  BAKERNEW YORKBaker / Tisch Capital (GP), LLC10% Owner NEW YORKBaker/Tisch Investments, LPNEW YORKAlane P  BarnesVP, General Counsel & Corp Sec RALEIGHAlane P  BarnesVP, General Counsel & Corp Sec DURHAMJ CLAUDE  BENNETTPresident BIRMINGHAMJ CLAUDE  BENNETTPresident BIRMINGHAMJ CLAUDE  BENNETTChief Operating Officer BIRMINGHAMStephen R  BiggarDirector BIRMINGHAMStephen R  BiggarDirector DURHAMCHARLES E  BUGGCEO, Chairman BIRMINGHAMCHARLES E  BUGGCEO BIRMINGHAMCHARLES E  BUGGDirector BIRMINGHAMFred E  CohenDirector SAN FRANCISCOFred E  CohenDirector FORT WORTHMICHAEL A  DARWINCFO BIRMINGHAMMICHAEL A  DARWINCFO 2190 PARKWAY LAKE DRMICHAEL A  DARWINPrincipal Accounting Officer BIRMINGHAMStanley C  ErckDirector GAITHERSBURGStanley C  ErckDirector BIRMINGHAMStanley C  ErckDirector DURHAMWILLIAM W  FEATHERINGILLDirector BIRMINGHAMWILLIAM W  FEATHERINGILLDirector BIRMINGHAMWILLIAM W  FEATHERINGILLDirector BIRMINGHAMCARL L  GORDONNEW YORKCARL L  GORDONNEW YORKCARL L  GORDONDirector BIRMINGHAM,CARL L  GORDONDirector BIRMINGHAMStuart  GrantSR VP & CFO BIRMINGHAMJOHN L  HIGGINSDirector DURHAMJOHN L  HIGGINSDirector BIRMINGHAMJOHN L  HIGGINSDirector BIMRINGHAMJOHN L  HIGGINSDirector BIRMINGHAMZOLA P  HOROVITZDirector BIRMINGHAMZOLA P  HOROVITZDirector DURHAMZOLA P  HOROVITZDirector BIRMINGHAMNancy J  HutsonDirector DURHAMNancy J  HutsonDirector STONINGTONROBERT A  INGRAMDirector Peder  JensenDirector DURHAMKENNETH B  LEE JRDirector KENNETH B  LEE JRDirector DURHAMROBERT S  LOWREYController, PAO DURHAMDavid  McCulloughVP BIRMINGHAMDavid  McCulloughVP DURHAMMike  MillsPrincipal Accounting Officer BIRMINGHAMJonathan M  NugentVP Corp Communications BIRMINGHAMJonathan M  NugentVP Corp Communications BIRMINGHAMSanj K  PatelDirector LEXINGTONLynne  PowellSenior VP - CCO DURHAMRANDALL B  RIGGSVP Business Development BIRMINGHAMRANDALL B  RIGGSSenior VP Business Development BIRMINGHAMCHARLES A  SANDERSDirector CHARLES A  SANDERSDirector BIRMINGHAMCHARLES A  SANDERSDirector DURHAMBETH C  SEIDENBERGDirector BIRMINGHAMWilliam P  SheridanSenior VP - CMO BIRMINGHAMWilliam P  SheridanSenior VP - CMO DURHAMJOSEPH H  SHERRILL JRDirector BIRMINGHAMJOSEPH H  SHERRILL JRDirector BIRMINGHAMWILLIAM M  SPENCER IIIDirector BIRMINGHAMWILLIAM M  SPENCER IIIDirector BIRMINGHAMTHOMAS R  STAAB IISenior Vice President and CFO DURHAMTHOMAS R  STAAB IISenior Vice President and CFO DURHAMRANDOLPH C  STEERDirector BIRMINGHAMRANDOLPH C  STEERDirector BIRMINGHAMJon P  StonehousePresident & CEO BIRMINGHAMJon P  StonehousePresident & CEO DURHAMPersons related to THOMAS R  STAAB II - INSPIRE PHARMACEUTICALS INCNamePositionCityGEORGE B  ABERCROMBIEDirector DURHAMGEORGE B  ABERCROMBIEDirector RALEIGHADRIAN  ADAMSPresident and CEO DURHAMADRIAN  ADAMSPresident and CEO RALEIGHADRIAN  ADAMSPresident and CEO RALEIGHMARY B  BENNETTExec. VP, Operations/Comm. DURHAMRICHARD  BOUCHERRICHARD  BOUCHER CHAPEL HILLKim  BrazzellSr. VP of Ophthalmic R & D DURHAMRomulus K  BrazzellEVP, Medical & Scientific DURHAMRomulus K  BrazzellEVP, Medical & Scientific RALEIGHRomulus K  BrazzellEVP, Medical & Scientific RALEIGHDEERFIELD CAPITAL LPNEW YORKDEERFIELD INTERNATIONAL LTDROAD TOWN, TORTOLA D8DEERFIELD INTERNATIONAL LTDROAD TOWN, TORTOLAMANAGEMENT CO /NY  DEERFIELDNEW YORKDEERFIELD PARTNERS, LPNEW YORKDeerfield Special Situations Fund International LTDROAD TOWN, TORTOLADeerfield Special Situations Fund, L.P.NEW YORKRICHARD M  EVANSVP, Pharmaceutical Development RALEIGHRICHARD M  EVANSVP, Pharmaceutical Development RALEIGHRICHARD M  EVANSVP, Pharmaceutical Development DURHAMJames E  Flynn10% Owner NEW YORKKIP  FREYDirector CHAPEL HILLKIP  FREYDirector DURHAMKIP  FREYDirector RALEIGHGREAT POINT PARTNERS LLC10% Owner GREENWICHALAN F  HOLMERDirector MCLEANALAN F  HOLMERDirector DURHAMALAN F  HOLMERDirector RALEIGHNancy J  HutsonDirector DURHAMNancy J  HutsonDirector RALEIGHJEFFREY R  JAYGREENWICHJEFFREY R  JAYGREENWICHJEFFREY R  JAYGREENWICHCharles A  JohnsonEVP of R&D & Chief Med. Ofcr. DURHAMCharles A  JohnsonEVP of R&D & Chief Med. Ofcr. RALEIGHCHARLES R  KAYENEW YORKCHARLES R  KAYENEW YORKCHARLES R  KAYENEW YORKDONALD J  KELLERMANSenior VP, Development RALEIGHDONALD J  KELLERMANSenior VP, Development DURHAMDONALD J  KELLERMANSenior VP, Development DURHAMDONALD J  KELLERMANSenior VP, Development DURHAMDONALD J  KELLERMANSenior VP, Development DURHAMRichard S  KentDirector DURHAMRichard S  KentDirector DURHAMRichard S  KentDirector RALEIGHANDREW I  KOVENEVP & Chief Admin & Legal Ofc DURHAMANDREW I  KOVENEVP & Chief Admin & Legal Ofc RALEIGHJOSEPH  LANDYNEW YORKJOSEPH  LANDYNEW YORKJOSEPH  LANDYNEW YORKKENNETH B  LEE JRDirector RALEIGHKENNETH B  LEE JRDirector DURHAMKENNETH B  LEE JRDirector DURHAMJONATHAN S  LEFFDirector NEW YORKJONATHAN S  LEFFDirector NEW YORKGREGORY J  MOSSINGHOFFPresident DURHAMGARY D  NOVACKGARY D  NOVACKDirector SAN RAFAELBarry G  PeaExec. VP, Corp. Dev. & GC DURHAMWILLIAM R  RINGOWILLIAM R  RINGODirector SAN FRANCISCOWILLIAM R  RINGODirector DURHAMWILLIAM R  RINGODirector CARMELWILLIAM R  RINGODirector FREMONTJOSEPH K  SCHACHLESr. VP, Sales & Marketing DURHAMJOSEPH K  SCHACHLEEVP, Pulmonary Business DURHAMJOSEPH K  SCHACHLEEVP, Pulmonary Business RALEIGHCHRISTY L  SHAFFERCHRISTY L  SHAFFERChief Executive Officer DURHAMCHRISTY L  SHAFFERChief Executive Officer DURHAMCHRISTY L  SHAFFERChief Executive Officer DURHAMCHRISTY L  SHAFFERChief Executive Officer DURHAMCHRISTY L  SHAFFERChief Executive Officer DURHAMCHRISTY L  SHAFFERPresident & CEO DURHAMJoseph M  SpagnardiSenior VP, GC & Secretary DURHAMJoseph M  SpagnardiSenior VP, GC & Secretary RALEIGHTHOMAS R  STAAB IIChief Financial Officer DURHAMTHOMAS R  STAAB IIEVP, CFO & Treasurer DURHAMTHOMAS R  STAAB IIEVP, CFO & Treasurer RALEIGHW LEIGH MD PHD  THOMPSONDirector CHARLESTONWARBURG PINCUS & CONEW YORKWARBURG PINCUS & CONEW YORKWarburg Pincus IX LLCNEW YORKWarburg Pincus IX LLCNEW YORKWARBURG PINCUS LLCNEW YORKWARBURG PINCUS LLCNEW YORKWARBURG PINCUS LLCNEW YORKWarburg Pincus Partners LLCNEW YORKWarburg Pincus Partners LLCNEW YORKWarburg Pincus Private Equity IX, L.P.10% Owner NEW YORKWarburg Pincus Private Equity IX, L.P.10% Owner NEW YORKBENJAMIN R  YERXASenior Vice Pres., Discovery DURHAMBENJAMIN R  YERXAEVP & Chf, Research & Develop DURHAM












 






Request unsuccessful. Incapsula incident ID: 574000390089284195-171762777361089144






BioCryst Pharmaceuticals Inc. :: Leadership Team







































HomeAbout BioCrystCompany OverviewPartners & Business DevelopmentLeadership TeamBoard of DirectorsCorporate GovernanceCommittee CompositionCode of Business ConductCommittee ChartersCareersOpportunitiesOur SciencePipeline & ProductRAPIVABNext generation kallikrein inhibitors for HAEBCX4430InvestorsAnalyst CoverageEvents & PresentationsEmail AlertsFinancial ProfileInvestor FaqInformation RequestNewsProxy OnlineSEC DocumentsStock InformationContact IRNews & ResourcesLatest NewsHAE PublicationsBCX4430 Publications







Leadership Team 




Home | Contact Us | Site Map




GO








Print this page




Leadership Team 






Leadership Team 


Jon P. Stonehouse, President, Chief Executive Officer
Thomas R. Staab, II, Senior Vice President, Chief Financial Officer
William P. Sheridan, MB BS, Senior Vice President, Chief Medical Officer
Yarlagadda S. Babu, Ph.D., Senior Vice President, Drug Discovery
Alane Barnes, Vice President, General Counsel & Corporate Secretary
Elliott Berger, Ph.D., Senior Vice President, Regulatory Affairs
Lynne Powell, Senior Vice President & Chief Commercial Officer
Dr. Carol Ohmstede, Vice President of Project Management
Robert Stoner, Vice President, Human Resources






Jon P. Stonehouse

President, Chief Executive Officer

Jon P. Stonehouse, a pharmaceutical executive for more than 20 years, has strong commercialization, financial transaction, business development and management expertise. He most recently served as Senior Vice President of Corporate Development at Merck KGaA with responsibility for global licensing and business development, corporate mergers and acquisitions, corporate strategic planning and alliance management. Among his accomplishments, he was responsible for leading the effort to develop a strategy for Merck that significantly changed the company. This culminated with the acquisition of Serono, S.A., the largest biotechnology company in Europe at the time of the agreement.


Back to Top








Thomas R. Staab, II

Senior Vice President, Chief Financial Officer

Tom Staab joined the BioCryst Leadership Team in July 2011, bringing his skill and experience regarding the financial stewardship of publically-traded companies, development and commercialization of pharmaceutical products and raising capital through strategic partnerships, equity and debt financings. Mr. Staab most recently served as Executive Vice President, CFO and Treasurer of Inspire Pharmaceuticals from May 2003 through its $430 million acquisition by Merck & Co., Inc. in May 2011. Prior to joining Inspire, he held the senior financial positions of Acting CFO and Treasurer at Triangle Pharmaceuticals, Inc. through its $480 million acquisition by Gilead Sciences, Inc. Additionally, Mr. Staab spent eight years working for PricewaterhouseCoopers LLP providing audit and business advisory services to national and multi-national corporations in the biotechnology, pharmaceutical, pulp and paper and communications industries. Tom currently serves on the Executive Committee of the Board of Directors of the North Carolina Biosciences Organization (“NCBIO”) as its Chairman and previously served as the Chairman of its Audit Committee.

He is a Certified Public Accountant and received a B.S. in Business Administration and a Masters of Accounting from the University of North Carolina at Chapel Hill.


Back to Top








William P. Sheridan, MB BS

Senior Vice President, Chief Medical Officer

Dr. William Sheridan joined BioCryst in July 2008. Dr. Sheridan is a seasoned biotechnology professional. During a 15-year tenure at Amgen, Dr. Sheridan organized and led the company's U.S. Medical Affairs function, making significant contributions to the successful launch of many compounds, including Aranesp®, Enbrel®, Kineret®, Neulasta® and Sensipar®, and led several product development teams. At Amgen, Dr. Sheridan held titles at the Vice President level in North American Medical Affairs, International Medical Affairs, Global Health Economics and Outcomes Research, U.S. Medical Affairs, and Product Development. He played an integral role in building Amgen's domestic and international medical affairs functions and in forming the health economics and outcomes unit. Dr. Sheridan earned his MB BS degree (M.D. equivalent) at the University of Melbourne in Victoria, Australia. Dr. Sheridan is a board-certified fellow of the Royal Australasian College of Physicians (FRACP), with a sub-specialty in medical oncology, and a Fellow of the American College of Physicians.

Back to Top








Yarlagadda S. Babu, Ph.D.

Senior Vice President, Drug Discovery

Dr. Babu directs a team of structural biologists, medicinal chemists and research biologists and oversees the structure-based drug discovery program at the company. Dr. Babu was BioCryst's first full-time employee having joined the Company in 1988. Prior to joining BioCryst, he served five years on the biochemistry faculty at the University of Alabama at Birmingham (UAB). He obtained his Ph.D. from the Indian Institute of Science, Bangalore and spent three years in the Laboratory of Molecular Biophysics at the University of Oxford, UK before joining UAB. He has over 70 scientific publications in peer-reviewed journals, and a number of issued and pending patents to his credit.

Back to Top








Alane Barnes

Vice President, General Counsel & Corporate Secretary

Alane Barnes joined BioCryst in 2006 and is responsible for all legal affairs of the company including but not limited to all contract negotiations, SEC compliance, corporate governance, IP strategy and management, licensing transactions, government contract management and dispute resolution. She graduated magna cum laude from Cumberland School of Law in 1997 and is a member of Curia Honoris, scholar of merit. Currently, she serves on the Board of the Biotechnology Association of Alabama and has served as a mentor for Alabama Launchpad, a competition created to fuel the development of companies in Alabama. Mrs. Barnes has also spoken at national conferences regarding the pharmaceutical business and at other women’s success conferences. She is a 2010 graduate of MOMENTUM, an organization geared toward building leadership in women.

Back to Top








Elliott Berger, Ph.D.

Senior Vice President, Regulatory Affairs

Dr. Elliott Berger joined BioCryst in August 2007. Dr. Berger has more than 30 years of experience in the pharmaceutical industry, including over 25 years devoted to management of regulatory affairs supporting new drug and biologic development. Prior to joining BioCryst, he was Vice President, Regulatory Affairs and Quality Assurance, Head of Global Regulatory Strategy at EMD Pharmaceuticals, the North American subsidiary of Merck KGaA. As part of the EMD start-up team, Dr. Berger built and managed the EMD Regulatory Affairs, Clinical Quality Assurance and Drug Safety Groups, as well as the Global Regulatory Strategy Group. At EMD, Dr. Berger submitted and managed over 10 Investigational New Drug Applications (NDA) in areas of oncology, diabetes, cardiovascular disease and neurology. Dr. Berger also prepared and submitted the NDA for Cyanokit ® which was approved within 6 months of submission to the FDA. Prior to EMD, Dr. Berger was a member of the Senior Executive Team at Astra Pharmaceuticals, most recently serving as Vice President, Regulatory Affairs.Dr. Berger received both his Ph.D. and M.S. degrees in Biometrics as well as his B.A. degree in Mathematics from Temple University.

Back to Top








Lynne Powell

Senior Vice President & Chief Commercial Officer

Ms. Lynne Powell joined BioCryst Pharmaceuticals as Senior Vice President and Chief Commercial Officer in January 2015. In this role, Lynne’s primary responsibility will be to formulate BioCryst’s global commercial strategy and to build the global organization that launches our oral kallikrein inhibitors for the prophylactic treatment of hereditary angioedema. Ms. Powell brings 24 years of industry experience to BioCryst. Most recently she served as Senior Vice President of North American Commercial Operations at CSL Behring. In this role, she was accountable for the financial performance and general management of CSL Behring’s commercial activities within the U.S. and Canada. Throughout her 17 year career at CSL Behring, Ms. Powell assumed increasing responsibilities within the R&D, and commercial functions of the organization. She has significant global experience gained as Vice President, Global Commercial Development and Head of Business Development & European Marketing. Ms. Powell launched five products globally for rare diseases, including hereditary angioedema (HAE). Prior to CSL, she held positions of increasing responsibility within GlaxoWellcome’s commercial strategy and clinical research organizations.


Back to Top








Dr. Carol Ohmstede

Vice President of Project Management

Dr. Carol Ohmstede joined BioCryst Pharmaceuticals in July 2016 as Vice President of Project Management. Dr. Ohmstede has approximately 30 years of experience in the pharmaceutical industry including 18 years focused on project & program management of new molecular entities from Research through Commercialization. Prior to joining BioCryst, she was Senior Director of Project and Portfolio Management – Liver Diseases at Gilead Sciences where she directed a team of project managers focused on the development of new drugs against Hepatitis C, Hepatitis B and nonalcoholic steatohepatitis (NASH). As part of the Liver Diseases team at Gilead, she was the program manager for the development and launch of Sovaldi® and Harvoni® for the treatment of chronic Hepatitis C. Previously, Dr. Ohmstede was at Trimeris, where she served in roles of increasing responsibility in project and portfolio management of the HIV Fusion Inhibitor program resulting in the development and launch of Fuzeon® in partnership with Hoffmann-La Roche. At BioCryst, Dr. Ohmstede will oversee the project management of the HAE portfolio and coordinate the management of the overall BioCryst project portfolio.

Back to Top








Robert Stoner

Vice President, Human Resources

Mr. Robert Stoner joined BioCryst in January 2008. Mr. Stoner brings more than 28 years of progressive Human Resources experience to BioCryst, having worked in a diverse group of industries during his career. Prior to joining BioCryst, Mr. Stoner served as Senior Vice President Human Resources at Smith Breeden Associates, Inc. an institutional financial management company in Chapel Hill, North Carolina. Prior to joining Smith Breeden Associates, Mr. Stoner held the position of Vice President Human Resources at EMD Pharmaceuticals, the North American subsidiary of Merck KGaA. At EMD, Mr. Stoner was responsible for human resource functions for multiple locations and was a member of the Global HR Team, coordinating and directing global HR initiatives within North America.Mr. Stoner participated in and graduated from the Merck University Executive Management Program, attending Northwestern University, Kellogg School of Management, Hong Kong University of Science and Technology and INSEAD in Paris. Mr. Stoner received his B.S. in Business Administration from Southern Illinois University.

Back to Top


























Staab Thomas R II - SEC Form 4 Insider Trading Screener - OpenInsider











OpenInsider

Latest

Latest Cluster Buys
Latest Insider Trading (all filings)
Latest Insider Purchases
Latest Insider Purchases $25k+
Latest Officer Purchases $25k+
Latest CEO/CFO Purchases $25k+
Latest Insider Sales
Latest Insider Sales $100k+
Latest Officer Sales $100k+
Latest CEO/CFO Sales $100k+


Top

Top Officer Purchases Today
Top Officer Purchases Past Week
Top Officer Purchases Past Month
Top Insider Purchases Today
Top Insider Purchases Past Week
Top Insider Purchases Past Month
Top Insider Sales Today
Top Insider Sales Past Week
Top Insider Sales Past Month


By Symbol

Officer Purchases $25k+ Today
Officer Purchases $25k+ Past Week
Officer Purchases $25k+ Past Month
Officer Sales $100k+ Today
Officer Sales $200k+ Past Week
Officer Sales $500k+ Past Month
Officer Sales $100k+ Today (no opt-ex)
Officer Sales $200k+ Past Week (no opt-ex)
Officer Sales $500k+ Past Month (no opt-ex)
Insider Purchases of Penny Stocks, Past Month
Insider Sales of Penny Stocks, Past Month


Charts

Contact











Staab Thomas R II - SEC Form 4 Insider Trading ScreenerCIK: 1230708 - Address: 4505 Emperor Blvd., Suite 200, Durham, NC 27703 




General

Tickers
Insider
Sh Price $



Lqdty M$






Date

Filing Date

All dates
Custom
Latest day
Last 3 days
Last 1 week
Last 2 weeks
Last 1 month
Last 2 months
Last 3 months
Last 6 months
Last 1 year
Last 2 years
Last 4 years



  



Trade Date

All dates
Custom
Latest day
Last 3 days
Last 1 week
Last 2 weeks
Last 1 month
Last 2 months
Last 3 months
Last 6 months
Last 1 year
Last 2 years
Last 4 years



  


Filing Delay



N Days Ago








Transaction Filing

 P - Purchase S - Sale A - Grant D - Sale to Iss G - Gift F - Tax M - Option Ex X - Option Ex C - Cnv Deriv W - Inherited

 No deriv


 Multiple Days

Traded K$



Own Chg %








Industry




All Sectors (except Funds)
Agriculture, Forestry, Fish
Mining
Construction
Manufacturing
Transportation & Utilities
Wholesale Trade
Retail Trade
Financial
Services
Closed-End Funds


























Insider Title

  Officer
    COB
    CEO
    Pres
    COO
    CFO
    GC
    VP
  Director
  10% Own
  Other






Group by


Filing
Company





Company Totals

Num Filings



Num Insiders



Num Officers



Traded K$



Own Chg %







Sort by

Filing Date
Trade Date
Ticker Symbol
Trade Value


Max Results
Page


clear


Real-time CSV, Options, Alerts








9 results -  -  -  -  -  -  - TCcnt1d1w1m6mS9-1-1-18-28 


X
Filing Date
Trade Date
Ticker
Insider NameInsider Title
Trade Type 
Share Price
Shares Traded
Shares Owned
Own chg
Value Traded
1d ret
1w ret
1m ret
6m ret



D2017-03-22 10:40:592017-03-20 BCRXStaab Thomas R IISVP, CFOS - Sale+OE$9.20-3,250141,460-2%-$29,900+3+4-20
D2017-03-14 13:47:432017-03-10 BCRXStaab Thomas R IISVP, CFOS - Sale+OE$9.06-3,250117,313-3%-$29,445-3+7-16
D2017-03-10 16:19:092017-03-08 BCRXStaab Thomas R IISVP, CFOS - Sale+OE$8.43-6,500117,313-5%-$54,763-3-1-19
D2017-03-08 08:05:542017-03-06 BCRXStaab Thomas R IISVP, CFOS - Sale+OE$7.90-3,250117,313-3%-$25,675+8+8-3
D2016-12-21 10:42:492016-12-19 BCRXStaab Thomas R IISVP, CFOS - Sale+OE$7.45-3,250124,187-3%-$24,213-4-4-14
M2016-08-15 14:07:462016-08-11 BCRXStaab Thomas R IISVP, CFOS - Sale$5.18-5,864124,187-5%-$30,388-6-14-16+16
2016-08-11 13:53:152016-08-09 BCRXStaab Thomas R IISVP, CFOS - Sale$4.43-14,577130,051-10%-$64,576+1-14-13+20
2015-12-22 15:45:442015-12-21 BCRXStaab Thomas R IISVP, CFOS - Sale$10.86-3,052136,592-2%-$33,145-3-1-32-74
2015-12-18 14:54:172015-12-17 BCRXStaab Thomas R IISVP, CFOS - Sale$10.49-3,000139,644-2%-$31,4700+4-27-72
Real-time CSV? Options? Alerts? Contact us!



AAmended filing
DDerivative transaction in filing (usually option exercise)
EError detected in filing
MMultiple transactions in filing; earliest reported transaction date and weighted average transaction price


S - SaleSale of securities on an exchange or to another personS - Sale+OESale of securities on an exchange or to another person (after option exercise)F - TaxPayment of exercise price or tax liability using portion of securities received from the companyP - PurchasePurchase of securities on an exchange or from another person 

Return to top
Copyright © 2017 openinsider.com. All rights reserved.












